The American Society of Clinical Oncology (ASCO) recently developed recommendations for the treatment of patients with metastatic colorectal cancer (mCRC).
More Research Needed on MMPs, Especially in CRC Patients With IBD
An important research focus in colorectal cancer concerns the enzymes comprising the 24-member matrix metalloproteinase (MMP) family of zinc- and calcium-dependent endopeptidases.
Understanding of KRAS Variations and Their Management Is Evolving
Since 2010, KRAS molecular testing has been guideline-recommended in the VA healthcare system. The goal has been to help determine how metastatic cancer is likely to respond to anti-EGFR drug therapy.
VA Pushes to Increase Uptake of Genomic, Other Precision-Testing in CRC
Patients receiving oncology care within a VHA facility are eligible for genomic- and other precision-testing, if they have an advanced-stage tumor or blood cancer and can tolerate recommended therapies.
Epidemiological Changes in CRC Will Have Significant Impact on VHA
The VA treats about 3% of all cases of colorectal cancer (CRC) in the United States each year—6% among cases in men. So, any epidemiological changes have an outsized effect on the nation’s largest integrated healthcare system.